Treatment of depression with selective serotonin inhibitors: the role of fluvoxamine

References

• World Health Organization http://www.who.int/mental_health/management/depression/definition/en/ (accessed December 2006).
   Google Scholar
• Sokero TP, Melartin TK, Rytsala HJ, Leskela US, Lestela-Mielonen PS, Isometsa ET. Suicidal ideation and attempts among psychiatric patients with major depressive disorder. J Clin Psychiatry 2003; 64: 1094–100
   PubMed Web of Science ®Google Scholar
• Lieberman JA. History of the use of antidepressants in primary care. Primary Care Companion. J Clin Psychiatry 2003; 5(Suppl 7)6–10
   Google Scholar
• Peretti S, Judge R, Hindmarch I. Safety and tolerability considerations: Tricyclic antidepressants vs. selective serotonin reuptake inhibitors. Acta Psychiatr Scand 2000; 403: 17–25
   Web of Science ®Google Scholar
• Aberg-Wistedt A, Agren H, Ekselius L. Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. J Clin Psychopharmacol 2000; 20: 645–52
   PubMed Web of Science ®Google Scholar
• Franchini L, Gasperini M, Perez J. A double-blind study of long-term treatment with sertraline or fluvoxamine for prevention of highly recurrent unipolar depression. J Clin Psychiatry 1997; 58: 104–7
   PubMed Web of Science ®Google Scholar
• Kroenke K, West SL, Swindle R. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care. A randomized trial. J Am Med Assoc 2001; 286: 2947–55
   PubMed Web of Science ®Google Scholar
• Rapaport M, Coccaro E, Sheline Y. A comparison of fluvoxamine and fluoxetine in the treatment of major depression. J Clin Psychopharmacol 1996; 16: 373–8
   PubMed Web of Science ®Google Scholar
• Suri RA, Altshuler LL, Rasgon NL. Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder. J Clin Psychiatry 2000; 61: 942–6
   PubMed Web of Science ®Google Scholar
• Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005; 143(6)415–26
   PubMed Web of Science ®Google Scholar
• Zajecka J, Amsterdam JD, Quitkin FM. Changes in adverse events reported by patients during 6 months of fluoxetine therapy. Psychiatry 1999; 60: 389–94
   Google Scholar
• Fredericson Overo K, Toft B, Christophersen L, Gylding-Sabroe JP. Kinetics of citalopram in elderly patients. Psychopharmacology (Berlin) 1985; 86: 253–7
   PubMed Web of Science ®Google Scholar
• Staab JP, Evans DL. Efficacy of venlafaxine in geriatric depression. Depress Anxiety 2000; 12(Suppl 1)63–8
   PubMed Web of Science ®Google Scholar
• Wagner W, Hauser V, Wong L. The safety profile of fluvoxamine in elderly patients. Hum Psychopharmacol 1996; 11: 267–72
   Web of Science ®Google Scholar
• Alexopoulos GS. New concepts for prevention and treatment of late-life depression. Am J Psychiatry 2001; 158: 835–8
   PubMed Web of Science ®Google Scholar
• Burkhart KS. Diagnosis of depression in the elderly patient. Lippincotts Prim Care Pract 2000; 4: 149–62
   PubMedGoogle Scholar
• Geddes JR, Butler R. Depressive disorders. Am Fam Phys 2002; 65: 1395–7
   PubMed Web of Science ®Google Scholar
• Montano CB. Primary care issues related to the treatment of depression in elderly patients. J Clin Psychiatry 1999; 60(Suppl 10)45–51
   PubMed Web of Science ®Google Scholar
• Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther 2000; 85: 11–28
   PubMed Web of Science ®Google Scholar
• Ereshefsky L, Riesenman C, Lam, YW. Antidepressant drug interactions and the cytochrome P450 system. The role of cytochrome P450 2D6 Clin Pharmacokinet 1995;29((Suppl 1)):10–19.
   PubMedGoogle Scholar
• Roberts R, Joyce P, Kennedy MA. Rapid and comprehensive determination of cytochrome P450 poor metabolizer genotypes by multiplex polymerase chain reaction. Hum Mutat 2000; 16: 77–85
   PubMed Web of Science ®Google Scholar
• Brosen K, Naranjo CA. Review of pharmacokinetic and pharmacodynamic interaction with citalopram. Eur Neuropychopharmacol 2001; 11: 275–83
   PubMed Web of Science ®Google Scholar
• Charlier C, Broly F, Lhermitte M. Polymorphisms in the CYP2D6 gene: association with plasmatic concentrations of fluoxetine and paroxetine. Ther Drug Monit 2003; 25: 738–42
   PubMed Web of Science ®Google Scholar
• Brosen K. Differences in interactions of SSRIs. Int Clin Psychopharmacol 1998; 13(Suppl 5)S45–7
   Web of Science ®Google Scholar
• Alfaro CL, Lam YW, Simpson J, Ereshefsky L. CYP2D6 status of extensive metabolizers after-multiple dose of fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 1999; 19: 155–63
   PubMed Web of Science ®Google Scholar
• Brosen K. Some aspects of genetic polymorphism in the biotransformation of antidepressants. Therapie 2004; 59: 5–12
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors – an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32(Suppl 1)1–21
   PubMed Web of Science ®Google Scholar
• Hemeriyck A, Bepaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. Curr Drug Metab 2002; 3: 13–37
   PubMed Web of Science ®Google Scholar
• Schmider J, Greenblatt DJ, von Moltke LL. Inhibition of CYP2C9 by SSRIs in vitro: studies of phenytoin p-hydroxilation. Br J Clin Pharmacol 1997; 280: 927–33
   Google Scholar
• Weller EB, Tucker S, Weller RA. The selective serotonin reuptake inhibitors controversy in the treatment of depression in children. Curr Psychiatry Rep 2005; 7(2)87–90
   PubMedGoogle Scholar
• Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 2004; 363(9418)1341–5
   PubMed Web of Science ®Google Scholar
• Wong IC, Besag FM, Santosh PJ, Murray ML. Use of selective serotonin reuptake inhibitors in children and adolescents. Drug Saf 2004; 27(13)991–1000
   PubMed Web of Science ®Google Scholar
• Walkup JT. Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group. New Engl J Med 2001; 344(17)1279–85
   PubMed Web of Science ®Google Scholar
• Riddle MA, Reeve EA, Yaryura-Tobias JA, et al. Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiat 2001; 40(2)222–9
   PubMed Web of Science ®Google Scholar
• Cheer SM, Figgitt DP. Spotlight on fluvoxamine in anxiety disorders in children and adolescents. CNS Drugs. 2002; 16(2)139–44
   PubMed Web of Science ®Google Scholar
• Nakao T, Nakagawa A, Yoshiura T, et al. Brain activation of patients with obsessive-compulsive disorder during neuropsychological and symptom provocation tasks before and after symptom improvement: a functional magnetic resonance imaging study. Biol Psychiatry 2005; 57(8)901–10
   PubMed Web of Science ®Google Scholar
• Ho Pian KL, van Megen HJ, Ramsey NF, et al. Decreased thalamic blood flow in obsessive-compulsive disorder patients responding to fluvoxamine. Psychiatry Res 2005; 138(2)89–97
   PubMed Web of Science ®Google Scholar
• Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptor in rat brain. Eur J Pharmacol 1996; 307: 117–19
   PubMed Web of Science ®Google Scholar
• Gonzalez-Alvear GM, Thompson-Montgomery D, Deben SE, Werling LL. Functional and binding properties of sigma receptors in rat cerebellum. J Neurochem 1995; 65: 2509–16
   PubMed Web of Science ®Google Scholar
• Shimazu S, Katsuki H, Takenaka C. Sigma receptor ligands attenuate N-methyl-D-aspartate cytotoxicity in dopaminergic neurons of mesencephalic slice cultures. Eur J Pharmacol 2000; 388: 139–46
   PubMed Web of Science ®Google Scholar
• Moison D, De Deurwaerdere P, Cagnotto A. Intrastriatal administration of sigma ligands inhibits basal dopamine release in vivo. Neuropharmacology 2003; 45: 945–53
   PubMed Web of Science ®Google Scholar
• Hornfeldt CS, Kitto KF, Larson AA. Evidence that the NH2-terminus of substance P modulates N-methyl-D-aspartate induced activity by an action involving sigma receptors. Eur J Pharmacol 1996; 306: 15–22
   PubMed Web of Science ®Google Scholar
• Maurice T, Urani A, Phan VL, Romieu P. The interaction between neuroactive steroids and the sigma1 receptor function: behavioral consequences and therapeutic opportunities. Brain Res Brain Res Rev 2001; 37: 116–32
   PubMed Web of Science ®Google Scholar
• Maurice T, Phan VL, Urani A, Guillemain I. Differential involvement of the sigma(1) receptor in the anti-amnesic effect of neuroactive steroids, as demonstrated using an in vivo antisense strategy in the mouse. Br J Pharmacol 2001; 134: 1731–41
   PubMed Web of Science ®Google Scholar
• Maurice T. Beneficial effect of the sigma(1) receptor agonist PRE-084 against the spatial learning deficits in aged rats. Eur J Pharmacol 2001; 431: 223–7
   PubMed Web of Science ®Google Scholar
• Maurice T, Phan VL, Privat A. The anti-amnesic effects of sigma1 (sigma1) receptor agonists confirmed by in vivo antisense strategy in the mouse. Brain Res 2001; 898: 113–21
   PubMed Web of Science ®Google Scholar
• Senda T, Matsuno K, Okamoto K, Kobayashi T, Nakata K, Mita S. Ameliorating effect of SA4503, a novel sigma 1 receptor agonist, on memory impairments induced by cholinergic dysfunction in rats. Eur J Pharmacol 1996; 315: 1–10
   PubMed Web of Science ®Google Scholar
• Lambert MT, Trutia C, Petty F. Extrapyramidal adverse effects associated with sertraline. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22: 741–8
   PubMed Web of Science ®Google Scholar
• Kamei H, Kameyama T, Nabeshima T. Effects of sigma receptor ligands on conditioned fear stress. Methods Find Exp Clin Pharmacol 1998; 20: 613–18
   PubMedGoogle Scholar
• Maurice T, Phan VL, Urani A, Kamei H, Noda Y, Nabeshima T. Neuroactive neurosteroids as endogenous effectors for the sigma1 (sigma1) receptor: pharmacological evidence and therapeutic opportunities. Jpn J Pharmacol 1999; 81: 125–55
   PubMedGoogle Scholar
• Hong WM, Werling LL. Evidence that the sigma-1 receptor is not directly coupled to G proteins. Eur J Pharmacol 2000; 408: 117–25
   PubMed Web of Science ®Google Scholar
• Phan VL, Urani A, Romieu P, Maurice T. Strain differences in sigma-1 receptor-mediated behaviours are related to neurosteroid levels. Eur J Neurosci 2002; 15: 1523–34
   PubMed Web of Science ®Google Scholar
• Langa F, Condony X, Tovar V. Generation and phenotypic analysis of sigma receptor type 1 (sigma 1) in knockout mice. Eur J Neurosci 2003; 18: 2188–96
   PubMed Web of Science ®Google Scholar
• Zanardi R, Franchini L, Serretti A, Perez J, Smeraldi E. Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study. J Clin Psychiatry 2000; 61: 26–9
   PubMed Web of Science ®Google Scholar
• Sonawalla SB, Spillmann MK, Kolsky AR. Efficacy of fluvoxamine in treatment of major depression with comorbid anxiety disorders. J Clin Psychiatry 1999; 60: 580–3
   PubMed Web of Science ®Google Scholar
• Bacaltchuk J, Hay P. Antidepressants versus placebo for people with bulimia nervosa Cochrane Database Syst Rev 2003;(4):CD003391.
   PubMedGoogle Scholar
• Ayuso-Gutierrez JL, Palazon M, Ayuso-Mateos JL. Open trial of fluvoxamine in the treatment of bulimia nervosa. Int J Eat Disord 1994; 15(3)245–9
   PubMed Web of Science ®Google Scholar
• Fichter MM, Leibl C, Kruger R, Rief W. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa. Pharmacopsychiatry 1997; 30(3)85–92
   PubMed Web of Science ®Google Scholar
• Milano W, Siano C, Putrella C, Capasso A. Treatment of bulimia nervosa with fluvoxamine: a randomized controlled trial. Adv Ther 2005; 22(3)278–83
   PubMed Web of Science ®Google Scholar
• Isbister GK, Bowe SJ, Dawson A, Whyte IM. Relative toxicity of selective serotonin reuptake inhibitors (SSRIs) in overdose. J Toxicol Clin Toxicol 2004; 42: 277–85
   PubMed Web of Science ®Google Scholar
• Kelly CA, Dhaun N, Laing WJ. Comparative toxicity of citalopram and the newer antidepressants after overdose. J Toxicol Clin Toxicol 2004; 42: 67–71
   PubMed Web of Science ®Google Scholar
• Fergusson D, Doucette S, Cranley Glass K. Association between suicide attempts and selective serotonin reuptake inhibitors: systematic review of randomised controlled trials. Br Med J 2005; 330: 396–402
   PubMed Web of Science ®Google Scholar
• Martinez C, Rietbrock S, Wise L. Antidepressant treatment and the risk of fatal and non–fatal self harm in first episode depression: nested case-control study. Br Med J 2005; 330: 389–95
   PubMed Web of Science ®Google Scholar
• Isacsson G, Holmgren P, Ahlner J. Selective serotonin reuptake inhibitor antidepressants and the risk of suicide: a controlled forensic database study of 14 857 suicides. Acta Psychiatr Scand 2005; 111: 286–90
   PubMed Web of Science ®Google Scholar
• Isacsson G, Holmgren P, Druid H, Bergman U. Psychotropics and suicide prevention. Implications from toxicological screening of 5281 suicides in Sweden 1992–1994. Br J Psychiatry 1999; 174: 259–65
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Hur K, Bhaumik DK, Mann JJ. The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 2005; 62: 165–72
   PubMed Web of Science ®Google Scholar
• Buchberger R, Wagner W. Fluvoxamine: safety profile in extensive post-marketing surveillance. Pharmacopsychiatry 2002; 35(3)101–8
   PubMed Web of Science ®Google Scholar
• Ottovenger EA. The efficacy of fluvoxamine in patients with severe depression. Prog Neuro-Psychopharmacol Biol Psychiatry 1994; 8: 731–740
   Google Scholar
• Dewulf L, Hendrickx B, Lesaffre E. Epidemiological data of patients treated with fluvoxamine: results from a 12 week non-comparative multicentre study. Int Clin Psychopharmacol 1995; 9(Suppl 4)67–72
   PubMed Web of Science ®Google Scholar
• Davis P, Kenarney K, Murdell D, Zabak K. The potential for elderly suicide: is health care missing?. Director 2001; 9: 122–5
   PubMedGoogle Scholar
• Paunovic VR, Jasovic M. Serotonergic control of behaviour: fluvoxamine and suicidal syndrome. Iugoslav Physiolo Pharmacol Acta 1989; 25: 403–9
   Google Scholar